Skip to main
CLGN
CLGN logo

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd has shown significant advancements in its strategic positioning within the regenerative medicine and aesthetics sectors, bolstered by a long-lasting patent expected to expire in 2039, which reinforces its competitive edge. The partnership with AbbVie has already yielded $24 million in milestone payments from a total potential of $50 million, reflecting strong market confidence in CollPlant’s rhCollagen technology. Additionally, the company's focus on cost optimization and preparations for human trials further amplifies its long-term growth potential and operational efficiency, enhancing its overall financial outlook.

Bears say

CollPlant Biotechnologies Ltd is experiencing challenges in generating consistent revenues, with dependence on its rhCollagen product sales and collaborations for financial stability. The company operates in multiple international markets, but its reliance on niche segments such as medical aesthetics and tissue engineering may hinder broad revenue growth. Additionally, while the proprietary technology presents a high barrier to entry for competitors, the market's overall uncertainties and CollPlant's financial performance metrics suggest potential headwinds that may affect future profitability.

CLGN has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 4 analysts, CLGN has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.